Japan’s Dementia Drug Market To Expand To 250 Billion By 2020
This article was originally published in PharmAsia News
Fuji Keizai recently put together a report on the growing dementia drug market in Japan, and concluded that 2011 sales of ¥127.4 billion will double to ¥257.1 billion by the year 2020.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.